Discontinuation of biologic therapy in patients with rheumatoid arthritis and ankylosing spondylitis: analysis from multicenter cohort studyN. El Ouardi, A. Bezza, A. El Maghraoui et al.|Rheumatology International|2022Cited by 11
One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registryS. Fellous, F. Allali, Hanan Rkain et al.|Rheumatology International|2021Cited by 10
Prevalence of latent tuberculosis before biotherapy initiation in rheumatoid arthritis and spondyloarthritis: data from the Moroccan biotherapy registryLamia Oulkadi, R. Bahiri, S. Rostom et al.|Rheumatology International|2021Cited by 9
Extra-Articular Manifestations in Patients with Ankylosing Spondylitis: Baseline Characteristics from the RBSMR StudyN. El Ouardi, L. Achemlal, O. Mkinsi et al.|Mediterranean Journal of Rheumatology|2022Cited by 8
Characteristics of Late-Onset Spondyloarthritis: Data from the Moroccan Registry of Biological Therapies in Rheumatic DiseasesA. Mougui, I. El Bouchti, Ihsane Hmamouchi et al.|Cureus|2023Cited by 6